Patents Represented by Attorney Louis C. Cullman
  • Patent number: 6565741
    Abstract: The desulfurization of petroleum distillates can be carried out by cyclic low-temperature adsorption of oxidized sulfur compounds with activated carbon followed by regeneration of the activated carbon using an organic solvent. The activated carbon used in the process is commercially available and its surface area that ranges from approximately 500 to 2000 m2/g having a substantial portion of its pores in the range between 10 to 100 Angstroms.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: May 20, 2003
    Inventors: William Wismann, Santosh K. Gangwal
  • Patent number: 6485633
    Abstract: The demercaptanizaiton of petroleum distillates can be carried out by sorption of the mercaptan with activated carbon and oxidation of the sorbed mercaptan to disulfide at between approximately 20° C. to 55° C. The activated carbon used in the process is commercially readily available. Its surface area typically ranges from between approximately 500 to 1500 m2/g and has substantial percentage of the pores in the 10 to 100 Angstrom range.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: November 26, 2002
    Assignee: DS2 Tech, Inc.
    Inventors: William Wismann, Santosh K. Gangwal
  • Patent number: 6471967
    Abstract: Vaccines and immunotherapeutics for preventing intracellular pathogen diseases in mammals are provided that consist of recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens. Exemplary vaccines and immunotherapeutics include attenuated recombinant Mycobacteria expressing the major extracellular non-fusion proteins of Mycobacteria and/or other intracellular pathogens. These exemplary vaccines are shown to produce surprisingly potent protective immune responses in mammals that surpass those of any previously known anti-mycobacterium vaccine. More specifically, a recombinant BCG expressing the 30 kDa major extracellular non-fusion protein of Mycobacterium tuberculosis is provided. Additionally, methods for preventing and treating diseases caused by intracellular pathogens are provided.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: October 29, 2002
    Assignee: The Regents of the University of California
    Inventors: Marcus A. Horwitz, Gunter Harth
  • Patent number: 6458560
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: October 1, 2002
    Assignees: Chiron Corporation, Washington University
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilva Frolov
  • Patent number: 6451592
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Grant
    Filed: October 6, 1997
    Date of Patent: September 17, 2002
    Assignees: Chiron Corporation, Washington University
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilya Frolov
  • Patent number: 6410316
    Abstract: Retroviral vector particle producing cells are provided, wherein the cell (a) has greater than 5 stably integrated copies of a retroviral vector construct; (b) produces greater than 10 infectious recombinant retroviral vector particles per cell per day; and (c) produces replication incompetent retroviral vector particles.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: June 25, 2002
    Assignee: Chiron Corporation
    Inventors: Philip L. Sheridan, Mordechai Bodner, Nicholas J. DePolo, Sybille Sauter, Stephen M. W. Chang
  • Patent number: 6391632
    Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as is compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: May 21, 2002
    Assignees: Chiron Corporation, Washington University
    Inventors: Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilya Frolov
  • Patent number: 6379691
    Abstract: Methods are provided for delivering nitric oxide to the vascular tissue of a patient to inhibit or prevent restenosis or improve vascular function following various surgical procedures or associated with various NO-related conditions. The disclosed methods comprise contacting the vascular tissue of a patient with a medical device coated with a coating comprising nitric oxide associated with and releaseable from a polyurea network formed from the reaction on said medical device of a polyisocyanate; an amine donor and/or hydroxyl donor; an isocyanatosilane adduct having terminal isocyanate groups and at least one hydrolyzable alkoxy group bonded to silicon; and optionally a polymer selected from the group consisting of polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, and polyacrylic acid.
    Type: Grant
    Filed: November 30, 2000
    Date of Patent: April 30, 2002
    Assignee: Medtronic/AVE, Inc.
    Inventors: Eugene Tedeschi, Chirag B. Shah
  • Patent number: 6329201
    Abstract: Nucleic acid molecule are provided comprising a nucleic acid sequence which encodes, in order, an alphavirus capsid, a signal peptide, and an alphavirus E1 or E2 glycoprotein. Also provided are vectors encoding such nucleic acid molecules, and use of such vectors or expression cassettes to generate recombinant alphavirus particles and alphavirus packaging cell lines. In addition, modified alphavirus vector constructs are provided that permit reduced transgene expression during vector packaging, as well as methods of using such vector constructs for the production of alphavirus vector particles.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: December 11, 2001
    Assignee: Chiron Corporation
    Inventors: John M. Polo, Thomas W. Dubensky, Jr., Stephen F. Hardy, Silvia Perri
  • Patent number: 6309660
    Abstract: Universal, biocompatible coating platforms for articles intended to contact physiological fluids or tissues and associated methods of production are disclosed. The coating platforms of the present invention are composed of a polyelectrolyte molecular film containing one or more biologically active compounds. The molecular film is further complexed with the surface of an article by a crosslinked interpenetrating network (IPN) made from at least one multifunctional molecule and at least one crosslinking agent. The IPN may entrap additional biologically active compounds within the coating platform, or additional biologically active compounds may be bound to its outer surface. The coating platform of the present invention is ideally suited for providing medical devices with anti-thrombogenic coatings.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: October 30, 2001
    Assignee: Edwards Lifesciences Corp.
    Inventors: Li-Chien Hsu, Can B. Hu, Sun-De Tong